RT Journal Article
SR Electronic
T1 Acute tubulointerstitial nephritis with or without uveitis: a novel form of post-acute COVID-19 syndrome in children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.23.23284848
DO 10.1101/2023.01.23.23284848
A1 Marina Avramescu
A1 Pierre Isnard
A1 Sarah Temmam
A1 Agnès Chevalier
A1 Paul Bastard
A1 Mikael Attia
A1 Romain Berthaud
A1 Marc Fila
A1 Claire Dossier
A1 Julien Hogan
A1 Tim Ulinski
A1 Damia Leguevaques
A1 Férielle Louillet
A1 Edouard Martinez Casado
A1 Jean-Michel Halimi
A1 Sylvie Cloarec
A1 Ariane Zaloszyc
A1 Camille Faudeux
A1 Caroline Rousset-Rouvière
A1 Stéphanie Clavé
A1 Jérôme Harambat
A1 Edouard Rollot
A1 Thomas Simon
A1 Megan Nallet-Amate
A1 Bruno Ranchin
A1 Justine Bacchetta
A1 Florence Porcheret
A1 Josselin Bernard
A1 Amélie Ryckewaert
A1 Anne Jamet
A1 Jacques Fourgeaud
A1 Nicolas Da Rocha
A1 Philippe Pérot
A1 Nicolas Kuperwasser
A1 Naïm Bouazza
A1 Marion Rabant
A1 Jean-Paul Duong Van Huyen
A1 Matthieu P Robert
A1 Julien Zuber
A1 Jean-Laurent Casanova
A1 Marc Eloit
A1 Isabelle Sermet-Gaudelus
A1 Olivia Boyer
YR 2023
UL http://medrxiv.org/content/early/2023/01/26/2023.01.23.23284848.abstract
AB Background COVID-19 is a complex multisystem disease, frequently associated with kidney injury. Since the beginning of the COVID-19 pandemic, we observed a striking increase in the incidence of acute tubulointerstitial nephritis (aTIN) without or with uveitis (TINUs) among children. This prompted us to examine whether SARS-CoV-2 might be the underlying trigger.Methods We conducted a French nationwide retrospective cohort study. We included all consecutive children diagnosed with aTIN or TINUs of undetermined cause between April-2020 and March-2021. SARS-CoV-2 antibody responses were tested by a luciferase immunoprecipitation system and compared to age-matched controls. Immunohistochemistry, immunofluorescence and molecular microbiology analyses were performed on kidney biopsies.Results Forty-eight children were included with a median age at diagnosis of 14.7 years (9.4-17.6). aTIN and TINUs incidence rates increased 3-fold and 12-fold, respectively, compared to pre-pandemic years. All patients had impaired kidney function with a median eGFR of 31.9 ml/min/1.73m² at diagnosis. Kidney biopsies showed lesions of acute tubulointerstitial nephritis and 25% of patients had fibrosis. No patient had concomitant acute COVID-19. All 16 children tested had high anti-N IgG titers and one had anti-S IgGs. Next-generation sequencing failed to detect any infectious agents in kidney biopsies. However, SARS-CoV-2 RNA was detected by PCR in two kidney samples supporting a potential direct link between SARS-CoV-2 and aTIN/TINUs.Conclusions We describe a novel form of post-acute COVID-19 syndrome in children, unique in its exclusive kidney and eye involvement, and its distinctive anti-SARS-CoV-2 N+/S-serological profile. Our results support a causal association linking SARS-CoV-2 infection to this newly-reported burst of renal/eye inflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics board approval was granted by the local Ethics Committee of the Assistance Publique Hopitaux de Paris (Decision number: N 2022 0503154702). Informed consent was obtained from all parents or legal guardians; patients were informed about the purpose of the study and gave their assent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript